Obulytix has had an exciting start to the year, marked by important milestones and strengthening the contribution to the fight against antimicrobial resistance. Obulytix joined the END2AMR consortium, a new Innovative Health Initiative (IHI)-supported collaboration [...]
More news
The 10th AMR Conference in Basel once again brought together some of the most passionate [...]
February 26, 2026— INCATE (INCubator for Antibacterial Therapies in Europe), the antimicrobial incubator supporting the [...]
The INCATE Selection Committee has selected five promising ventures to receive Stage I support. Want [...]
February 3, 2026 — INCATE (INCubator for Antibacterial Therapies in Europe), the antimicrobial incubator supporting [...]
Every year, selecting the finalists for the Startup Pitch Event becomes more challenging, and 2026 [...]
January 21, 2026 – The Japan Pharmaceutical Manufacturers Association (JPMA) has joined forces with INCATE [...]
January 13, 2026 — INCATE (INCubator for Antibacterial Therapies in Europe), the antimicrobial incubator supporting [...]
Just before turning the page to 2026, it’s worth pausing to reflect on both the [...]
